Skip to main content

Table 8 Risk for primary, secondary, and tertiary individual CV end points with linagliptin versus total comparators based on Cox proportional hazards model

From: Cardiovascular safety of linagliptin in type 2 diabetes: a comprehensive patient-level pooled analysis of prospectively adjudicated cardiovascular events

  Cox HR (95% CI)
Primary end point  
CV death, MI, stroke, or 0.78 (0.55–1.12)
UAP with hospitalization  
Secondary end points  
CV death, stroke, or MI 0.74 (0.49–1.13)
All major CV events 0.82 (0.61–1.09)
FDA-custom MACE 0.70 (0.45–1.08)
Tertiary end points  
CV death 1.04 (0.42–2.60)
Non-fatal MI 0.86 (0.47–1.56)
Non-fatal stroke 0.34 (0.15–0.75)
TIA 0.09 (0.01–0.75)
UAP with hospitalization 1.08 (0.56–2.06)
Hospitalization for CHF* 1.04 (0.43–2.47)
Total mortality 0.89 (0.45–1.75)
  1. CHF, congestive heart failure; CI, confidence interval; CV, cardiovascular; FDA, Food and Drug Administration; HR, hazard ratio; MACE, major adverse CV events; MI, myocardial infarction; TIA, transient ischemic attack; UAP, unstable angina pectoris.
  2. *Includes data only from 8 trials with prospective independent adjudication of hospitalization for CHF (n = 3314).